- Home
- EAT vs IONS Comparison
EAT vs IONS Comparison
Compare EAT & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAT
- IONS
- Stock Information
- Founded
- EAT 1975
- IONS 1989
- Country
- EAT United States
- IONS United States
- Employees
- EAT N/A
- IONS N/A
- Industry
- EAT Restaurants
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- EAT Consumer Discretionary
- IONS Health Care
- Exchange
- EAT Nasdaq
- IONS Nasdaq
- Market Cap
- EAT 7.0B
- IONS 6.9B
- IPO Year
- EAT N/A
- IONS 1991
- Fundamental
- Price
- EAT $158.10
- IONS $43.78
- Analyst Decision
- EAT Hold
- IONS Buy
- Analyst Count
- EAT 16
- IONS 14
- Target Price
- EAT $175.14
- IONS $58.43
- AVG Volume (30 Days)
- EAT 1.4M
- IONS 2.0M
- Earning Date
- EAT 08-13-2025
- IONS 07-30-2025
- Dividend Yield
- EAT N/A
- IONS N/A
- EPS Growth
- EAT 144.71
- IONS N/A
- EPS
- EAT 8.32
- IONS N/A
- Revenue
- EAT $5,384,200,000.00
- IONS $944,050,000.00
- Revenue This Year
- EAT $5.74
- IONS $9.21
- Revenue Next Year
- EAT $5.18
- IONS $14.35
- P/E Ratio
- EAT $19.01
- IONS N/A
- Revenue Growth
- EAT 21.95
- IONS 16.05
- 52 Week Low
- EAT $65.26
- IONS $23.95
- 52 Week High
- EAT $192.22
- IONS $50.43
- Technical
- Relative Strength Index (RSI)
- EAT 46.69
- IONS 60.61
- Support Level
- EAT $149.06
- IONS $40.37
- Resistance Level
- EAT $167.79
- IONS $41.93
- Average True Range (ATR)
- EAT 6.12
- IONS 1.42
- MACD
- EAT 0.42
- IONS -0.03
- Stochastic Oscillator
- EAT 45.63
- IONS 66.61
About EAT Brinker International Inc.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.